HeartSciences Inc. (NASDAQ:HSCS) Stock Short Interest Climbs 126.1%

HeartSciences Inc. (NASDAQ:HSCS) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totaling 63,146 shares, an increase of 126.1% from the September 30th total of 27,931 shares. Approximately 1.3% of the company’s shares are sold short. Based on an average daily volume of 332,122 shares, the days-to-cover ratio is presently 0.2 days.

HeartSciences Stock Down 8.3%

NASDAQ:HSCS traded down $0.30 on Friday, reaching $3.31. 54,480 shares of the company’s stock were exchanged, compared to its average volume of 742,291. The firm has a market capitalization of $16.45 million, a price-to-earnings ratio of -1.03 and a beta of 1.76. HeartSciences has a 52-week low of $1.63 and a 52-week high of $5.25. The business has a fifty day moving average of $3.59 and a 200-day moving average of $2.73.

HeartSciences (NASDAQ:HSCS) last posted its quarterly earnings data on Monday, September 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.10 million. As a group, equities analysts anticipate that HeartSciences will post -2.99 earnings per share for the current year.

Analyst Ratings Changes

HSCS has been the subject of several research analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research report on Monday, September 21st. Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a research note on Sunday, September 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.00.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical technology company focused on improving the detection and assessment of heart disease through advanced electrocardiography (ECG). The company develops diagnostic tools designed to provide clinicians with additional information about cardiac function using a standard, noninvasive ECG test.

Its principal technology is the MyoVista ECG system, which uses the company’s proprietary wavelet-based ECG, or wavECG, technology. MyoVista is designed to assess mechanical aspects of the heart, including left ventricular diastolic function, which may help identify cardiac abnormalities that are not readily detected through conventional ECG analysis.